From smoking to COPD--current approaches

Area of Science:

• Pulmonology and Immunology
• Environmental Health

Background:

• Chronic obstructive pulmonary disease (COPD) is a major global cause of mortality, with cigarette smoking as a primary etiological factor.
• Despite extensive research, the pathophysiology and optimal treatment of smoking-induced COPD remain incompletely understood.
• Emerging research highlights the potential roles of autoimmune mechanisms and epigenetic modifications in COPD development.

Purpose of the Study:

• To explore the potential autoimmune origins of COPD, focusing on autoantibodies and immune complexes.
• To investigate the significance of epigenetic modifications, particularly those linked to maternal smoking, in COPD pathogenesis.
• To identify novel therapeutic strategies targeting autoimmune and epigenetic pathways in COPD.

Main Methods:

• Review of existing literature on autoantibodies in COPD patients.
• Analysis of studies investigating immune complex deposition in lung tissue.
• Examination of research on epigenetic alterations, including DNA methylation and histone modifications, in relation to smoking and COPD.
• Exploration of potential therapeutic interventions, such as deacetylation agents.

Main Results:

• Evidence suggests a possible autoimmune component in COPD, with autoantibodies and immune complexes implicated.
• Epigenetic modifications, influenced by factors like maternal smoking, are linked to COPD development and progression.
• Deacetylation agents show promise in potentially reversing epigenetic changes and mitigating steroid resistance.

Conclusions:

• The autoimmune aspect of COPD warrants further investigation for developing precise treatment strategies.
• Epigenetic modifications represent a critical area for understanding COPD pathogenesis and developing novel therapies.
• While novel treatments are explored, smoking cessation remains the cornerstone of COPD prevention and management.